




























Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Fan, A. X., Papadopoulos, G. L., Hossain, M. A., Lin, I-J., Hu, J., Tang, T. M., Kilberg, M. S., Renne, R.,
Strouboulis, J., & Bungert, J. (2014). Genomic and proteomic analysis of transcription factor TFII-I reveals
insight into the response to cellular stress. Nucleic Acids Research, 42(12), 7625-7641.
https://doi.org/10.1093/nar/gku467
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 24. Jan. 2021
Published online 29 May 2014 Nucleic Acids Research, 2014, Vol. 42, No. 12 7625–7641
doi: 10.1093/nar/gku467
Genomic and proteomic analysis of transcription
factor TFII-I reveals insight into the response to
cellular stress
Alex Xiucheng Fan1, Giorgio L. Papadopoulos2,3, Mir A. Hossain1, I.-Ju Lin1, Jianhong Hu4,
Tommy Ming Tang1, Michael S. Kilberg1, Rolf Renne4, John Strouboulis3,* and
Jörg Bungert1,*
1Department of Biochemistry and Molecular Biology, Center for Epigenetics, Genetics Institute, Powell Gene Therapy
Center, Gainesville, Florida, USA, 2Department of Biology, University of Crete, GR1409 Heraklion, Greece,
3Division of Molecular Oncology, Biomedical Sciences Research Center “Alexander Fleming”, Vari GR 16672,
Greece and 4Department of Molecular Genetics and Microbiology, College of Medicine, University of Florida,
Gainesville, Florida, 32610, USA
Received January 20, 2014; Accepted May 12, 2014
ABSTRACT
The ubiquitously expressed transcription factor TFII-
I exerts both positive and negative effects on tran-
scription. Using biotinylation tagging technology and
high-throughput sequencing, we determined sites of
chromatin interactions for TFII-I in the human ery-
throleukemia cell line K562. This analysis revealed
that TFII-I binds upstream of the transcription start
site of expressed genes, both upstream and down-
stream of the transcription start site of repressed
genes, and downstream of RNA polymerase II peaks
at the ATF3 and other stress responsive genes. At
the ATF3 gene, TFII-I binds immediately downstream
of a Pol II peak located 5 kb upstream of exon 1. In-
duction of ATF3 expression increases transcription
throughout the ATF3 gene locus which requires TFII-
I and correlates with increased association of Pol II
and Elongin A. Pull-down assays demonstrated that
TFII-I interacts with Elongin A. Partial depletion of
TFII-I expression caused a reduction in the associa-
tion of Elongin A with and transcription of the DNMT1
and EFR3A genes without a decrease in Pol II recruit-
ment. The data reveal different interaction patterns of
TFII-I at active, repressed, or inducible genes, iden-
tify novel TFII-I interacting proteins, implicate TFII-I
in the regulation of transcription elongation and pro-
vide insight into the role of TFII-I during the response
to cellular stress.
INTRODUCTION
TFII-I, also known as general transcription factor 2 I
(GTF2I), belongs to a family of related proteins that act
as transcription regulators (1,2). Genes encoding mem-
bers of this transcription factor (TF) family are deleted in
Williams–Beuren Syndrome patients (3). Mice homozygous
for a deletion of the TFII-I gene die early during embryonic
development with multiple defects (4). TFII-I is an unusual
TF; it is relatively large containing multiple protein–protein
interaction domains, and it associates with both expressed
and repressed genes (1,2,5). Functional studies have shown
that TFII-I can act as activator or repressor of transcrip-
tion, which is likely determined by the sequence context
and/or the interacting co-regulatory proteins.
TFII-I contains six R-repeats, also called I-domains, that
resemble but are different from the helix-loop-helix domain
(6). In addition, it also harbors a leucine zipper at the N-
terminus as well as a basic region involved in DNA binding
and a nuclear localization sequence (NLS). TFII-I is sub-
ject to post-transcriptional regulation by alternative splic-
ing and phosphorylation (3,7–9). Alternative splicing gen-
erates isoforms that are expressed at different levels in differ-
ent tissues (1,2). Phosphorylation of TFII-I has been shown
to regulate its translocation from the cytoplasm to the nu-
cleus (10,11). TFII-I is one of a few TFs for which specific
functions in the cytoplasm have been demonstrated (1,2).
For example, TFII-I has been shown to control the nu-
clear translocation of c-Rel, a regulator of the c-Myc TF
(12). Furthermore, TFII-I has been shown to associate with
phospholipase C- (PLC- ) and to compete for interac-
tions between PLC- and the transient receptor potential
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cation channel subfamily C member 3 (TRPC-3), thereby
inhibiting agonist-induced calcium entry (13).
Originally, TFII-I was isolated and characterized as an
activity that binds to the initiator sequence and mediates
transcription of genes that contain this basal promoter ele-
ment (14). In vitro studies demonstrated that TFII-I inter-
acts with the TFII-D complex and that it is able to recruit
transcription complexes to TATA-less promoters. While
binding of TFII-I to the initiator has been demonstrated for
a number of genes, TFII-I is not considered a general TF
but rather as a protein that regulates transcription of a se-
lected number of genes (1,2). In addition to interacting with
the initiator, TFII-I has been shown to interact with E-box
elements, mediated through interactions with TFs including
the bHLH proteins, USF and c-Myc (15,16). Furthermore,
TFII-I interacts with the so-called DICE (Downstream Im-
munoglobulin Control Element) sequences originally iden-
tified in specific immunoglobulin genes (17).
TFII-I has been reported to regulate many different
genes that encode proteins involved in cell-cycle regula-
tion, TGF-signaling, endoplasmic reticulum stress re-
sponse and immune signaling (1,2). Moreover, TFII-I regu-
lates genes that are expressed in a cell-type specific manner
including the vascular endothelial growth factor receptor-
2 and the -globin genes (18,19). TFII-I activates and
represses transcription by recruiting either co-activators
or co-repressors, including histone deacetylases, to target
genes (2,20,21).
A recent genome-wide ChIP/chip analysis of TFII-I in
embryonic stem cells and in embryonic tissues revealed that
TFII-I binds to a large number of genes involved in diverse
cellular processes (5,22). The correlation between binding
and gene expression was found to be low. This could be con-
sistent with its dual function as an activator or repressor.
However, Bayarsaihan et al. presented evidence that TFII-I
interacts with poised genes in embryonic stem (ES) cells that
are characterized by bivalent histone modifications, mean-
ing the genes are associated with nucleosomes that carry
both the H3K4me3 modification, typically found in tran-
scribed genes, and the H3K27me3 modification, usually as-
sociated with repressed genes (5,22). The authors speculated
that TFII-I may be involved in the marking of genes that
are expressed during lineage commitment steps. A switch
from repressor to activator function of TFII-I has been re-
ported to be involved in immunoglobulin heavy chain (IgH)
gene transcription (23). The repressed IgH-gene is associ-
ated with TFII-I and HDAC3. Upon activation, transcrip-
tion co-factor OCA-B replaces HDAC3 from TFII-I and
mediates interactions between the IgH promoter and an en-
hancer element.
In the present study, we identified TFII-I interacting pro-
teins and determined sites of chromosomal binding of TFII-
I in human K562 erythroleukemia cells. We generated and
expanded single K562 cell clones expressing the Escherichia
coli BirA ligase, which catalyzes biotinylation, or the E. coli
BirA ligase in addition to TFII-I fused to a biotinylatable
tag (24). Cells expressing BirA, or BirA together with bi-
otinylatable TFII-I were subjected to high-throughput se-
quencing and protein interaction analysis. The data reveal
novel interactions between TFII-I and nuclear proteins in-
volved in transcription regulation and identify DNA ele-
ments associated with TFII-I in erythroleukemia cells.
MATERIALS AND METHODS
DNA constructs, cell culture and stable transfections
For N-terminal biotin tagging of TFII-I, the coding
sequence of TFII-I was PCR amplified from plasmid
pTO-TFII-I (19) using the following primers: Fwd, 5′-
GCCGGCGGCCGCCCATATGGCCCAAGTTGC-3′
and Rev, 5′-CTGATCAGCGGGTTTAAACGGG3–
3′. Restriction enzyme sites for NotI and PmeI
were incorporated at the 5′ and the 3′ end, re-
spectively, by the PCR reaction. The vector
AviTEVFLAG/3xHANLSBirA/pBUDNeo was digested
with NotI and PmeI, treated with calf intestine phosphatase
and ligated with gel purified TFII-I coding fragment to
generate pFlag-biotin-TFII-I. The entire coding sequences
of TFII-I and BirA were verified by DNA sequencing.
K562 cells were grown in RPMI 1640 (Corning, Cellgro)
containing 10% fetal bovine serum (FBS) and 1% penicillin-
streptomycin. The cells were grown in 5% CO2 at 37◦C and
kept at a density between 1 × 105 and 2 × 106 cells/ml.
Transfection of the pFlag-biotin-TFII-I expression con-
struct or of the control vector expressing only BirA was
carried out by nucleofection using the Amaxa Nucleofector
kit (Amaxa, VCO-1001N) according to the protocol pro-
vided by the manufacturer. At 40 h after transfection, cells
were subjected to G418 selection at 350 or 400 g/ml for
14 days before cells were frozen down or expanded and sub-
jected to western blotting experiments, protein purification
or ChIP analysis. K562 cells expressing the Flag/biotin-
tagged TFII-I were subjected to single clone selection using
dilution and growth in 96-well plates. Single clones were ex-
panded and subjected to western blot analysis using Flag-
specific antibodies.
Streptavidin-mediated protein pull-down
Nuclear extracts were prepared from K562 cells express-
ing BirA or BirA together with bio-tagged TFII-I accord-
ing to a procedure published previously (25). Streptavidin-
mediated pull-down was performed as described by Ro-
driguez et al. (26,27) with minor modifications. Briefly, 2
mg nuclear extract was used for each pull-down using 50
l/mg streptavidin-coated magnetic beads (Dynabeads M-
280, Life Technologies AS., Oslo, Norway). The beads were
washed 3 times with phosphate buffered saline (PBS) at
room temperature (RT) and then blocked with 200 g/ml
chicken egg albumin (CEA, Sigma Alderich, A5503-IG) in
a final volume of 1 ml in HENG buffer (10 mM HEPES
[pH 9], 1.5 mM MgCl2, 0.25 mM EDTA, 20% glycerol, 1
mM PMSF, 1mM DTT) while rotating at RT for 1 h. The
salt concentration of the nuclear extract was adjusted to 150
mM NaCl and protease inhibitors (Complete, Roche) and
NP-40 (0.3% final concentration) were added. After remov-
ing the blocking buffer, the beads were mixed with the nu-
clear extract in HENG buffer (containing 150 mM NaCl,
0.3% NP-40, protease inhibitors) and incubated in the pres-
ence of 5 l/mg protein benzonase (Novagen, 25 U/l) for
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concentrated on a magnetic rack and washed 6 times for
10 min using HENG buffer with 300 mM NaCl and 0.3%
NP-40. The beads were resuspended in 1 × Laemmli buffer
and the proteins were eluted by boiling. Proteins were sub-
jected to sodium dodecyl sulphate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) followed by western blotting or
trypsin digestion of gel pieces. The trypsin-digested samples
were then analyzed using an LTQ Orbitrap XL mass spec-
trometer system (Thermo Scientific, Waltham, MA, USA)
and analyzed as described previously (28).
Streptavidin-mediated pull-down of chromatin and massive
parallel sequencing
Streptavidin-mediated pull-down of cross-linked biotiny-
lated chromatin was performed by the procedure published
by He and Pu (29). Briefly, 4 × 107 K562 cells expressing ei-
ther BirA or BirA together with bio-tagged TFII-I (clones 5
and 18) were cross-linked with 1% formaldehyde for 7 min.
The reaction was quenched by adding glycine to a final con-
centration of 125 mM. After a wash in hypotonic buffer,
the cross-linked material was resuspended in ChIP dilution
buffer and subjected to sonication to yield fragments with
an average length of 150–200 bp. An aliquot of 25 l was
taken and stored at −20◦C. 50 l Dynabeads M-280 Strep-
tavidin (Life Technologies AS., Oslo, Norway, 11205D) and
Dynabeads Protein A (Life Technologies AS., Oslo, Nor-
way, 10002B) (per 6 × 107 cells) were washed three times
in PBS/1% bovine serum albumin and blocked for 1 h at
4◦C. Sheared chromatin was pre-cleared using Protein A
beads at 4◦C for 1 h. The protein A beads were centrifuged
and the supernatant was incubated together with the mag-
netic beads at 4◦C overnight. The bound material was col-
lected with a magnet and the beads were washed several
times using SDS wash buffer, high-salt buffer, LiCl buffer
and finally Tris-EDTA (TE) buffer as outlined by He and
Pu (29). The cross-links, including that of the input sam-
ples, were reversed by incubating the beads in SDS-ChIP
dilution buffer and incubation at 70◦C overnight. The sam-
ples were treated with proteinase K and RNAse and DNA
was purified using the QIAquick PCR purification kit as per
the manufacturer’s instruction. The quality of the bioChIP
DNA was verified by qPCR using c-Fos promoter primers
and examined using the Agilent 2100 Bioanalyzer (Agi-
lent, Santa Clara, CA, USA). The bioChIP-seq DNA was
then converted to a library for sequencing on the Illumina
Genome Analyzer 2 according to the Illumina Multiplex-
ing Sample Preparation Guide (www.illumina.com). Deep
sequencing was carried out for two independent clones of
bioTFII-I (clones 5 and 18) and one clone of BirA trans-
fected K562 cells. All 36-nucleotide sequence reads pro-
duced were mapped to the UCSC hg18 Human Genome
Assembly using the bowtie.2 algorithm (30). Sequence reads
with multiple genome alignments and/or more than 2 nu-
cleotide mismatches were excluded from subsequent analy-
sis, whereas identical sequence reads were counted as one.
Peak calling was performed using the Model-based Analy-
sis for ChIP-Seq (MACS) algorithm (31) with default pa-
rameters. The two bioTFII-I aligned reads were merged to-
gether and analyzed versus the BirA data set using default
parameters. Gene mapping was performed in the R envi-
ronment using the ChIPpeakAnno package (32) and the
TSS.human.NCBI36 gene location reference.
Peak locations for all K562 data sets used in this study
were directly downloaded from the Encode database (http:
//genome.ucsc.edu/ENCODE/) (33,34). Accession num-
bers of the data sets used here are included in Supple-
mentary Table S1. Overlaps were computed using the
‘find-OverlappingPeaks’ function included in the ChIP-
peakAnno package (32).
Co-immunoprecipitation (Co-IP) and immunoblotting
Co-IP was carried out as described by Rodriguez et al. (26).
Briefly, 50 l magnetic protein G beads (Dynabeads Protein
G, Life Technologies AS., Oslo, Norway) per 500 g pro-
tein were rinsed three times with PBS and twice with 100
mM sodium citrate (pH 5.0). Antibodies (6–8 g per 500
g protein) were added to the beads in 1 ml HENG buffer
(10 mM HEPES-KOH, pH 9.0, 1.5 mM MgCl2, 0.25 mM
EDTA, 20% glycerol, 1 mM PMSF and 1 mM DTT) and
the samples were incubated for 2 h at RT while rotating. The
beads were rinsed twice with 100 mM sodium citrate (pH
5.0) and once with 200 mM triethanolamine (pH 8.2). Af-
ter addition of 20 mM dimethyl pimelimidate dihydrochlo-
ride (Sigma-Alderich, D8388, in 200 mM triethanolamine,
pH8.2) the beads were incubated for 45 min at RT while ro-
tating. The beads were rinsed once with 50 mM Tris, pH 7.5,
and three times with PBS containing 0.01% Tween 20. The
immunoglobulin G (IgG) and antibody beads were blocked
with 200 g/ml CEA by incubating while rotating for 1 h at
RT. Nuclear protein extracts were incubated for 30 min at
RT with 2.5 l benzonase (Novagen) per 500 g protein and
then diluted with HENG buffer to bring the KCl concentra-
tion to 125 mM. The nuclear extracts were pre-cleared with
the blocked IgG beads for 1 h at 4◦C, and then transferred
to the antibody beads and incubated overnight at 4◦C. The
IgG and control beads were washed 5 times for 5 min with
HENG wash buffer (HENG buffer plus 300 mM KCl) at
4◦C, rinsed twice with PBS and proteins were eluted off the
beads by incubation in 30 l 1xLaemmli buffer for 10 min at
80◦C. The immunoblotting procedure was performed as de-
scribed by Barrow et al. (35). Briefly, 10–20 g protein was
loaded onto 4–15% (wt/vol) TGX Tris-HCl gels (Bio-Rad)
and subjected to electrophoresis. The proteins were trans-
ferred to Polyvinylidene fluoride (PVDF) membranes and
incubated with antibodies. The following antibodies were
used in these experiments: from Santa Cruz Biotechnol-
ogy, TFII-I (sc-9943), Brg1 (sc-374197), TopoII (sc-
5346), GAPDH (sc-25778), rabbit IgG (sc-2027), mouse
IgG (sc-2025); from Bethyl Laboratories, SMARCC2
(A301-038A), TopoII (A300-950A), TCEB3 (A300-
942A); from Cell Signalling, SMARCC1 (11956S); from
Biolegend, TAF15 (ab-134616); from Affinity Bioreagents
-HA (OPA1-10980); from Sigma, -FLAG M2 (F3165).
RNA interference
The TFII-I target siRNA as well as the negative control
siRNA pools and the transfection reagent were purchased
from Thermo Scientific (siGENOME GTF2I SMARTpool
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#2 [D-001210-02-05] and DharmaFECT1 [T-2001-03]).
siRNA-mediated knockdown was performed in K562 cells
according to the siRNA transfection protocol provided
by Thermo Scientific DharmaFECT. Briefly, the siRNA
pools and DharmaFECT transfection reagent were diluted
in serum-free RPMI medium and incubated for 5 min at
RT. Then the siRNA pools and DharmaFECT transfec-
tion reagent were mixed together and incubated at RT for
20 min. Antibiotic-free complete RPMI medium and the
ready-to-use siRNA transfection mix was added to K562
cells using two concentrations of the TFII-I siRNA pool (25
and 50 nM) in separate experiments. Then, the cells were in-
cubated at 37oC in 5% CO2 for 24–48 h for mRNA analysis
or 48–96 h for protein analysis.
For generating stable K562 cells expressing TFII-I spe-
cific (shTFII-I) or scrambled shRNA (scrambled con-
trol, SC) cells were transfected with the pGIPZ-shTFII-
I or the pGIPZ-shSc vectors (Thermo Scientific) using
lipofectamin 2000 (Invitrogen) according to the proce-
dure provided by the manufacturer. Briefly, 5 × 105
cells were transfected with 5 g DNA in 2 ml of
RPMI medium supplemented with 10% FBS and 1%
penicillin/streptomycin. Cells were subjected to selection
in the presence of 2 g/l puromycin. Subsequently, sin-
gle cell clones were selected and the transfected K562 cells
were maintained and expanded in RPMI medium con-
taining 10% FBS, 1% penicillin/streptomycin and 1 g/l
puromycin. The following antisense sequences were used:
shRNA TFII-I, 5′-TTCATACACTGCAATGCAG-3′; SC,
5′-TCTCGCTTGGGCGAGAGTAAG-3′.
RNA extraction, cDNA synthesis and quantitative PCR
RNA was extracted from wild-type K562 cells or K562 cells
expressing BirA or BirA together with bio-tagged TFII-I
(clones 5 and 18) using the RNeasy kit (Qiagen) and reverse
transcribed using the Iscript cDNA synthesis kit (Bio-Rad).
Quantitative PCR was performed as described before (35)
using primers listed in Supplementary Table S2.
Chromatin immunoprecipitation
ChIP was performed as described by Barrow et al. (35)
with minor modifications. Briefly, 2 × 107 WT K562 cells
were cross-linked in 2% formaldehyde for 10 min at RT.
After quenching the reaction with glycine at 125 mM, the
chromatin was sonicated to yield fragments of 100–600
bp. For pre-clearing, the lysates with the cross-linked chro-
matin fragments were incubated with IgG (Santa Cruz;
sc-2025) for 2 h at 4◦C and then incubated with Dyn-
abeads Protein A/G (Life Technologies AS., Oslo, Nor-
way, 10002B/D). The lysates with the protein A beads were
put on a magnetic rack and the supernatant was incu-
bated with specific antibody on a rotating wheel at 4◦C
overnight. The beads were then washed with a series of
several low-salt, high-salt, and LiCl buffers. After reversal
of the crosslink at 65◦C overnight, the DNA was purified
by phenol/chloroform/isoamylalcohol and chloroform ex-
tractions and precipitated with 2.5 x volume 100% ethanol.
The pellets were washed with 70% ethanol, resuspended in
10 mM Tris-Cl (pH 8.5), and analyzed by qPCR as de-
scribed previously (35). The antibodies used for the ChIP
are described under the section Co-IP and western blotting.
Primer sequences for the qPCR analysis are listed in Sup-
plementary Table S2.
RESULTS
Generation of K562 cells expressing biotinylated TFII-I
To identify TFII-I target genes and interacting proteins,
we generated human erythroleukemia (K562) cells express-
ing the delta isoform of TFII-I bearing a biotinylatable
tag (bioTFII-I). Protein-biotinylation allows for highly effi-
cient and specific pull-down and isolation of protein com-
plexes and protein/chromatin fragments using streptavidin
beads (24,26–28). Furthermore the biotinylation approach
allowed us to focus on one specific isoform of TFII-I. There
are four different isoforms of TFII-I (1,2). The TFII-I delta
isoform is ubiquitously expressed and we therefore decided
to tag this isoform. Previous studies have analyzed TFII-
I genome-wide occupancy in differentiating ES cells using
ChIP followed by hybridization to microarrays (ChIP on
Chip) (5,22). The authors used antibodies against TFII-I
which did not discriminate between the different TFII-I iso-
forms (5,22).
We used a DNA plasmid that contained coding frag-
ments for a biotinylatable tag, a Flag-tag and a TEV pro-
tease cleavage site (Figure 1A). The insertion of TFII-I
cDNA into this plasmid generated a coding sequence that,
when expressed, introduces the Flag/bio-tag into the N-
terminus of TFII-I. The plasmid also contains the cDNA
for the E. coli BirA protein ligase, which catalyzes the addi-
tion of biotin to the biotinylatable tag of the recombinant
TFII-I (36,37). Plasmids expressing the bio-tagged TFII-I
and BirA (pFlag-biotin-TFII-I) or BirA only were trans-
fected into K562 cells by nucleofection. Nuclear extracts
from stably transfected cells expressing bio-tagged TFII-
I/BirA or BirA alone were subjected to western blotting,
and antibodies specific for TFII-I marked a novel band in
the cells expressing BirA and the tagged protein that mi-
grated slightly slower than TFII-I, due to the inclusion of
the tag (Figure 1B). We generated two single cell clones that
express biotinylated TFII-I at equivalent levels (clone 5 and
18). HA-tagged BirA is expressed only in cells expressing
BirA or in cells expressing BirA and the bio-tagged TFII-I
(clone 5, Figure 1C, top). Biotinylated TFII-I is only de-
tectable in cells expressing both BirA and the tagged TFII-
I (Figure 1C, bottom). We next prepared nuclear protein
extracts from cells expressing BirA only or cells express-
ing BirA and biotin-tagged TFII-I (clone 5). These extracts
were subjected to pull-down using streptavidin-coated mag-
netic beads. Both the pull-down material as well as the su-
pernatant was subjected to SDS-PAGE and western blot-
ting using antibodies specific for TFII-I (Figure 1D). The
data show that TFII-I is efficiently pulled-down from ex-
tracts containing the biotinylated TFII-I but not from ex-
tracts that harbor the BirA ligase only. Figure 1E shows
a coomassie-blue stained SDS-PAGE gel with pulled-down
material from cells expressing BirA or cells expressing both
BirA and the bio-tagged TFII-I. The summary data demon-
strate that the tagged TFII-I was expressed in the K562 cells
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Figure 1. Identification of TFII-I interacting proteins in K562 cells
by streptavidin-mediated pull-down and mass spectrometry analysis. (A)
Structure of bio-tagged TFII-I and HA-tagged BirA. A cDNA construct
was generated expressing TFII-I with an N-terminal tag consisting of the
biotinylatable peptide (Bio), a TEV cleavage site and a Flag-peptide, as
well as the E. coli BirA protein biotin ligase containing an N-terminal
HA tag (3xHA) and a nuclear localization signal (NLS). (B) Nuclear ex-
tracts from K562 cells expressing BirA (BirA) or BirA together with the
bio-tagged TFII-I were fractionated by SDS-PAGE and analyzed by west-
ern blotting with antibodies specific for TFII-I (-TFII-I). (C) Nuclear
extracts from K562 cells (WT), K562 cells expressing BirA or single cell
clone 5 expressing bio-tagged TFII-I and BirA (TFII-I/5), were fraction-
ated by SDS-PAGE, transferred to a PVDF membrane and examined us-
ing an HA-specific antibody (-HA, top) or streptavidin conjugated horse
radish peroxidase (Streptavidin-HRP, bottom). (D) Single K562 cell clone
5 expressing bio-tagged TFII-I and BirA (TFII-I/5), or cells expressing
only BirA were subjected to pull-down using streptavidin-coated magnetic
beads. The supernatant and pull-down material was subjected to western
blotting using antibodies specific for TFII-I (-TFII-I) (E) Representative
image of coomassie-blue stained SDS-PAGE gels loaded with streptavidin
pulled-down material from K562 cells expressing only BirA (BirA) or BirA
together with bio-tagged TFII-I, in this case representing clone 5.
Genome-wide binding pattern of TFII-I in K562 cells
To analyze the global association of TFII-I with chro-
matin in K562 cells we performed streptavidin-mediated
pull-down of cross-linked, fragmented chromatin. These ex-
periments were performed in cells expressing only BirA or
in the two single cell clones expressing BirA together with
the Flag/biotin-tagged TFII-I (clones 5 and 18). The iso-
lated DNA was subjected to high-throughput sequencing
using the Illumina platform. For cells expressing biotiny-
lated TFII-I (Clone 5 and 18) we obtained 6.7 and 5.8 mil-
lion reads, respectively, and for cells expressing only BirA
we obtained 7 million reads. Given the very high correla-
tion observed between sequencing results obtained by the
two independent bioTFII-I ChIP sequencing experiments
(Figure 2A), we merged them into one data set. Using
the MACS algorithm (31), we assembled the unique, non-
redundant sequence reads into peaks that identify poten-
tial TFII-I bound regions across the genome. This approach
yielded a total of 18 920 potential TFII-I binding sites in
K562 cells. Each TFII-I peak was assigned to its nearest
gene, thus identifying a total of 5886 potential TFII-I target
genes in K562 cells. Location analysis of identified peaks
revealed selective binding of TFII-I in intergenic (∼68%)
rather than intragenic (∼31%) regions and a very small frac-
tion of peaks directly overlapping gene transcription start
or end sites (∼1%, transcription start site [TSS] and tran-
scription end site [TES], respectively) (Figure 2B). These
findings are in accordance with the results of previous ChIP-
chip experiments in mouse ES cells for TFII-I (5,22).
In order to assay for the expression state of the poten-
tial TFII-I target genes identified, we used the gene expres-
sion levels, determined by mRNA sequencing in K562 cells,
available from the Encode project (GSM5916660) (33,34).
Based on this analysis and using a ‘Reads per kilo base
per million’ (RPKM) cut-off value of 1, a total of 2994
(∼51%) TFII-I bound target genes are expressed, whereas
2893 (∼49%) are silent in K562 cells (Figure 2C), thus show-
ing no overt preference for TFII-I binding to either active or
inactive genes. This lack of association between gene expres-
sion and TFII-I binding is reminiscent of previous ChIP-
chip studies performed in mouse ES cells (5,22).
Even though there is no clear relationship between TFII-
I binding and target gene expression, if we compare the
occupancy profiles of TFII-I between expressed and silent
target genes, some distinct patterns begin to emerge (Fig-
ure 2D). The distribution of peaks mapping proximally (±2
kb from TSS) to expressed genes (green line) differs from
that of silent genes (red line). In expressed genes TFII-I
preferentially binds upstream of the TSS, whereas at silent
genes, TFII-I peaks are more evenly distributed upstream
and downstream of the TSS. Overall, TFII-I binding down-
stream of the TSS of repressed genes is more abundant
compared to expressed genes (P = 0.0026, chi-square test).
Additionally, in both upstream and downstream binding
events, TFII-I peaks associated with active genes are closer
to the TSS compared to silent genes (Supplementary Figure
S1, pupstream = 7e-4, pdownstream = 6e-4, Wilcoxon rank sum
test).
The differential binding patterns of TFII-I at active or re-
pressed genes is illustrated with a few examples in Figure 3.
The genes encoding for GATA-1, DNMT1, MLL2 and
CD81 are all expressed in K562 cells as revealed by the EN-
CODE RNA seq. (33,34). In each case, TFII-I binding was
strongly associated with sequences immediately upstream
of the TSS. On the other hand, genes encoding for EFR3A,
ZAP70, NCF1 and OSM, which are expressed near or be-
low detection in K562 cells, revealed peaks of TFII-I asso-
ciations either only downstream (EFR3A) or upstream and
downstream (NCF1, OSM and ZAP70) of the TSS.
To functionally characterize the role of TFII-I in gene ex-
pression, we inhibited expression of TFII-I by siRNA (Fig-
ure 4A). We focused on 6 genes for which we provided the
binding patterns of TFII-I in Figure 3. Figure 4A demon-
strates successful inhibition of TFII-I expression in cells
transfected with the TFII-I siRNA pool compared to cells
transfected with the control siRNAs (nonT). Expression of
the GAPDH, B2M and PgK1 genes, which did not associate
with TFII-I, were not affected by reduced levels of TFII-
I (Figure 4B). The mRNA levels of four expressed genes
(DNMT1, CD81, GATA1 and MLL2) decreased in cells
expressing diminished levels of TFII-I compared to cells
transfected with SC siRNAs (Figure 4C). Consistent with
the ENCODE data (33,34), the ZAP70 and OSM genes
were expressed at or below detection and the data show that
inhibition of TFII-I activity was not sufficient to increase
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Figure 2. Features of global TFII-I genomic interactions. (A) Distribution of raw sequencing reads 10 kb upstream and downstream of all annotated
TSS in cells expressing BirA only, or BirA together with biotinylated TFII-I (clones 5 and 18 as indicated). (B) Distribution of TFII-I binding peaks with
respect to the location of genes. TSS intragenic (exons or introns), TES, Downstream (downstream of the coding region), Upstream (upstream of the
coding region). (C) Correlation of TFII-I binding peaks and gene expression in K562 cells. Out of 6068 expressed genes in K562 cells, 2994 reveal a peak
for TFII-I binding. (D) Distribution of TFII-I binding peaks with respect to the TSS in expressed (green) and silent (red genes) genes in a 2 kb window.
The 0 depicts the TSS, – denotes upstream of the TSS and + denotes downstream of the TSS.
the genomic TFII-I binding analysis presented above. Gene
ontology (GO) analysis did not reveal any particular func-
tional association of TFII-I target genes. More importantly,
there was no meaningful functional distinction between ex-
pressed and silent TFII-I targets in the individual clusters of
genes (data not shown). This is in contrast to GO ontology
classification of TFII-I target genes in mouse ES cells which
identified enrichment for chromatin assembly, cell fate com-
mitment and signaling pathway ontologies (5). This con-
trast suggests differential TFII-I functions in mouse ES cells
versus committed human hematopoietic cells.
In order to identify putative DNA consensus sequences
associated with TFII-I binding sites we used the MEME-
ChIP algorithm (38), to perform de novo motif analysis on
the sequences underlying the TFII-I peaks (Figure 5A). A
region of 75 nucleotides around the summit of each TFII-I
peak that map within 10 kb or less from an annotated gene
TSS, was used as input in all subsequent analyses. Peaks
assigned to either expressed or silent TFII-I targets returned
nearly identical results (Figure 5A) with the most enriched
consensus being related to the HMG-box protein 1 (Hbp1)
consensus sites. E-box and GATA motifs as well as binding
sites for NFAT TFs were also found to be highly enriched in
both data sets. Discriminative motif analysis between peaks
assigned to expressed or silent genes did not produce any
notable differences.
In addition to the unbiased approach of the de novo anal-
yses, we performed a more targeted approach searching for
all consensus sequences associated with core RNA Pol II
promoters including the TATA box, Initiator (INR), Down-
stream Promoter Element (DPE), TFII-B recognition ele-
ment (BRE) and the TFII-I and BEN SELEX identified
consensus (RGATTR) (2,5) (Figure 5B). Peaks over 1 kb
upstream or downstream of a gene’s TSS were excluded
from this analysis. Again, peaks assigned to expressed or
non-expressed genes produced similar results, except for dif-
ferences in the BRE element. Interestingly, the BRE element
is overrepresented in TSS-proximal TFII-I peaks compared
to all TFII-I peaks (P < 2.2e-16, chi-square test). This is
in contrast to all other core RNA Pol II promoter elements
which show no preferential association with TSS-proximal
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Figure 3. TFII-I occupancy at four expressed and four silent genes in K562 cells. Transcription (RNA) and TFII-I binding peaks at the expressed
GATA1,DNMT1,MLL2 and CD81, as well as the non-expressed EFR3A, ZAP70, NCF1 and OSM genes. The scale refers to read counts that were
normalized using the peak calling algorithm (MACS). Arrows indicate the direction of transcription. The results shown for TFII-I represent the combined
data of clones 5 and 18.
erential association of TSS proximal TFII-I associated BRE
motifs with active genes (P = 0.0006, chi-square test). These
data suggest that TFII-I can distinguish BRE motifs de-
pending on their proximity to TSS, and to a lesser extent,
on their transcriptional status. Moreover, GO analysis of
BRE-containing active genes with a TFII-I peak within 1
kb upstream of the TSS (‘up expr 1 kb’ in Figure 5B) shows
enrichment for genes implicated in stress response (Table 1).
To further characterize the genomic loci occupied by
TFII-I in K562 cells we computed their overlaps with pub-
licly available genome-wide occupancy profiles provided by
the Encode project (33,34) (Figure 6). TFII-I peaks were
divided into different categories based on the expression
state of their target genes (expressed [6309 peaks] or silent
[12611 peaks]), their distance to the nearest TSS (proximal
[±1 kb from TSS, 1413 peaks]) or distal (over 1 kb from
TSS [17438 peaks]), and proximal peaks were further di-
vided with respect to the target gene’s TSS as upstream
(770 peaks) or downstream (643 peaks). Results are pre-
sented as a heatmap in Figure 6 and represent the percent-
age of TFII-I peaks that overlap with a specific histone tail
modification or TF peak within a 150 nt window. Consis-
tent with current models of gene regulation, TFII-I peaks
associated with expressed genes show a significant over-
lap with activating histone marks (H3K4me2, H3K4me3,
H3K9Ac, H3K27Ac, H3K4me1 and H3K36me3), whereas
TFII-I peaks associated with silent genes present the high-
est overlap with the H3K27me3 silencing histone mark. Ad-
ditionally, we found a very high preference of proximally
bound TFII-I peaks for specific TFs with respect to distal
TFII-I peaks. More specifically, we found significantly high
overlap of TFII-I with the E2F4 and E2F6 factors (∼50%)
in proximal peaks, followed by a series of E-box binding
TFs, such as c-Myc, Max, as well as c-Jun and c-Fos. TF c-
Myc interacts with E-box sequences (CANNTG), which are
also bound by USF proteins. This supports previous find-
ings showing that TFII-I interacts with c-Myc and USF at
initiator or E-box elements (15,16). The co-binding of E2Fs
and TFII-I is interesting in light of recent data showing that
E2Fs associate with the majority of active promoters in B-
lymphocytes (39). Overlap with GATA factors did not seem
to specifically associate with any subset of TFII-I peaks.
Distal TFII-I peaks seemed to be marked by the silencing
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Figure 4. Functional analysis of TFII-I with respect to selected target genes in K562 cells. (A) Western blot analysis of TFII-I expression in wild-type (WT)
K562 cells and in K562 cells transfected with siRNA pools against TFII-I at different concentrations (25 or 50 nM) or a non-targeting pool of siRNAs
(nonT). Analysis of GAPDH served as a protein loading control. (B) Analysis of GAPDH, B2M and PgK1 gene expression in WT K562 cells or K562
cells transfected with siRNA pools against TFII-I (TFII-I at 50 nM) or non-targeting (nonT) siRNA pools. RNA was extracted, reverse transcribed and
subjected to qPCR. (C) Analysis of TFII-I target gene expression in K562 cells transfected with siRNA pool against TFII-I (siTFII-I) or with non-targeting
siRNA (nonT). RNA was extracted from the cells, reverse transcribed and subjected to qPCR using primers specific for the TFII-I, DNMT1, CD81,
GATA1, MLL2, ZAP70 and OSM. Data in (B) and (C) were normalized to expression of GAPDH and the data represent two independent experiments
with the qPCR performed in triplicate +/− SEM. Statistical analysis was based on the students t-test with P < 0.05 for all differences observed between
nonT and siTFII-I data in (C).
Table 1. Enriched Gene Ontologies in genes with TSS upstream and proximal TFII-I peaks as well as harboring a BRE element (80 genes)
Category Term Count % P-value Genes
GO:0033554 cellular response to
stress











3 3.75 0.022 GTF2A2, GTF2H4,
POLR2D
GO:0006354 RNA elongation 3 3.75 0.025 GTF2A2, GTF2H4,
POLR2D
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Figure 5. Analysis of TF binding sites associated with TFII-I peaks. (A) Consensus sequences associated with TFII-I binding peaks (PWM: position weight
matrix) and corresponding TFs in expressed and silent (Not Expressed) genes. (B) Association of basal promoter elements and known TFII-I/Ben binding
sites with TFII-I peaks within 1 kb of the TSS in expressed and silent genes. Also shown are whether the peaks within 1 kb are upstream or downstream
of the TSS for the expressed subset of genes. The following sequence elements were examined; TATAAA (TATA-box), Initiator (INR, YYANWYY),
Downstream Promoter Element (DPE, RGWYV), TFII-B recognition element (BRE, SSRCGCC) and the TFII-I/Ben binding site (RGATTR).
TFII-I interacts with topoisomerase II  and , SWI/SNF
chromatin remodeling complexes, TAF15 and Elongin A
We performed a preliminary Mass-spec analysis of pro-
teins associated with TFII-I in clones 5 and 18. The cell
clones 5 and 18 as well as the control cells expressing only
the BirA ligase were expanded and subjected to large scale
nuclear protein extraction. The nuclear extracts were then
incubated with streptavidin-coated magnetic beads. After
several rounds of washing, as described in Materials and
Methods, proteins were eluted and either fractionated by
SDS-PAGE (Figure 1E) or directly subjected to trypsiniza-
tion ‘on-the-beads’. Protein samples were then analyzed by
Orbi-Trap Mass-Spec. In several experiments we identified
TFII-I, components of SWI/SNF chromatin remodeling
complexes, including Brg1, SMARCC1 and SMARCC2,
topoisomerases II  and , the TBP-associated factor
(TAF) 15 and transcription elongation factor Elongin A.
We confirmed interactions between the proteins and TFII-
I using stringent Co-IP experiments with nuclease treated
nuclear extracts (Figure 7). The interactions with Brg1,
SMARCC1, SMARCC2, Topo II, Topo II, TAF15 and
Elongin A (TCEB3) were confirmed by both TFII-I im-
munoprecipitation as well as reverse immunoprecipitations
with antibodies against TFII-I protein interacting partners
(Figure 7). Some of the proteins showed weak bands in the
western blotting experiments which could be due to the fact
that only a small fraction of TFII-I associated with these
proteins or that the interactions are unstable. Other pro-
teins, like TAF15, showed robust signals suggesting more
abundant interactions (Figure 7).
Next, we performed ChIP experiments to (i) verify that
TFII-I associates with selected target genes outlined in Fig-
ure 4 (see Supplementary Figure S2A) and (ii) to exam-
ine if TFII-I associated proteins co-occupy the same chro-
mosomal regions together with TFII-I (Figure 8). Supple-
mentary Figure S2A shows that TFII-I associated with 8
gene loci at which we detected peaks in the high-throughput
sequencing analysis, including GATA1, DNMT1, CD81–
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Figure 6. Association of TFII-I binding peaks with epigenetic marks or TF occupancy in K562 cells. Shown is a heatmap correlating TFII-I binding at
various positions relative to the TSS of expressed and silent genes with epigenetic marks and TF binding peaks in K562 cells (high correlations are in green,
lower correlations are in red). Numbers represent the percentage of TFII-I peaks that overlap with a specific histone tail modification or a TF-peak within
a 150 nt window.
cused our attention to four gene loci, two that are expressed
(DNMT1 and GATA-1), and two that are expressed at low
levels in K562 cells (OSM and EFR3A). As a negative con-
trol we examined a DNAse I insensitive region in the hu-
man -globin gene locus that is located in between two -
globin gene locus control region hypersensitive sites (HS2–
3) and not known to interact with TFs (33,34). All ChIP
data were normalized to the -globin locus control region
HS2–3 segment. The data demonstrate that endogenous
TFII-I associated with all of the gene loci identified by the
streptavidin-pull-down/high-throughput sequencing exper-
iment (Figure 8A and Supplementary Figure S2). Further-
more, all of the proteins that were shown to interact with
TFII-I in the Co-IP experiments associated together with
TFII-I at the expressed GATA1 and DNMT1 gene loci (Fig-
ure 8B). At the silent OSM gene, we only detected moderate
binding of TFII-I (Figure 8A). Interestingly, however, the
EFR3A gene associated with TFII-I, Pol II, and Elongin
A (TCEB3; Figure 8A and C). Comparison of the TFII-I
binding peak with the binding of Pol II and RNA-seq-data,
retrieved from the K562 ENCODE project data, revealed
that TFII-I associated immediately downstream of a Pol II
peak at the EFR3A promoter (Figure 8D). To analyze the
co-localization of TFII-I with TAF15, Elongin A and Pol
II in more detail we examined three different regions in the
DNMT1 and EFR3a gene loci by ChIP (Supplementary
Figure S2B). The data demonstrate that TAF15, Elongin A
(TCEB3), and Pol II localized together with TFII-I at the
TFII-I peak in the DNMT1 promoter. None of these pro-
teins revealed significant binding at regions 1 kb upstream
or downstream of the TFII-I peak compared to IgG pull
down. At the EFR3A region TFII-I, Elongin A and Pol II
associated with the TFII-I peak but not with a region 1 kb
upstream. We did not detect TFII-I binding at a region 1 kb
downstream of the TFII-I peak and the binding of Elongin
A and Pol II were significantly reduced at this site. Bind-
ing of TAF15 was not detected in the EFR3A gene locus
(Supplementary Figure S2), presumably due to the low tran-
scriptional status in K562 cells.
We next analyzed if reduced expression of TFII-I affects
the association of TAF15, Elongin A and Pol II at the
DNMT1 and EFR3A gene loci (Figure 9). We generated
single K562 cell clones expressing shRNA directed against
TFII-I (shTFII-I) or SC shRNA. The data show that TFII-
I expression at the RNA level was reduced by about 50% in
the shTFII-I clone compared to the control, whereas the re-
duction of TFII-I protein level appeared to be greater (Fig-
ure 9A and B). The decrease in TFII-I expression was as-
sociated with reduced expression of DNMT1 and EFR3A,
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Figure 7. Analysis of TFII-I interacting proteins by Co-IP. Nuclear ex-
tracts from K562 cells were subjected to immunoprecipitation using IgG
control or TFII-I antibodies. Proteins from the input (before IP), IgG pull-
down and TFII-I pull-down were fractionated by SDS-PAGE and sub-
jected to western blot analysis using the antibodies shown on the left or
antibodies specific for TFII-I (right panel).
GAPDH, UBB, B2M and PGK1. At both the DNMT1 and
the EFR3A genes, reduced expression of TFII-I led to a de-
crease in the association of Elongin A (TCEB3, Figure 9C).
However, the binding of TAF15 and Pol II was unperturbed
at these genes in cells expressing shTFII-I compared to con-
trol cells (SC, Figure 9C). These data suggest that TFII-I
regulates at least some genes at the level of transcription
elongation.
TFII-I associates with several genes involved in response to
cellular stress and binds immediately downstream of Pol II
peaks
Given that some of the proteins found to associate with
TFII-I (TAF15 and Elongin A) are known to be involved
in gene regulation during cellular stress (40,41), we ex-
amined the binding of TFII-I to several stress responsive
genes. TFII-I interacted with genes encoding for the heme-
regulated eIF2 kinase HRI (EIF2AK1), the Cockayne
syndrome-B (CS-B or ERCC6), heterochromatin protein 1
beta (Hp1 beta, CBX1) and TF ATF3 (Supplementary Fig-
ure S3). TFII-I bound at these stress responsive genes at
their 5′ ends and the genes revealed a peak of Pol II bind-
ing upstream of the TFII-I peak. We focused our attention
to TF ATF3, which is induced in response to amino acid
limitation and endoplasmic reticulum stress (42,43). Previ-
ous studies have shown that ATF3 expression is controlled
by two alternative promoters, P1, and P2 (Figure 10A) (41–
44). Promoter P1 is utilized in some cancer cell lines (44),
while P2 appears to be the dominant promoter in most cell-
types (42,43). Based on the ENCODE data, ATF3 is tran-
scribed at very low levels in K562 cells mediated by pro-
moter P2 (Figure 10A). The interaction of TFII-I with a
region 5 kb upstream of promoter P1 of the ATF3 gene
was striking and did not appear to fit the previous obser-
vations that TFII-I interacted with regions downstream of
the TSS in repressed genes (Figure 10A). Interestingly, sim-
ilar to what we observed at the repressed EFR3A gene, a
relatively large peak representing Pol II binding is immedi-
ately upstream of the TFII-I binding peak within the ATF3
gene locus. The presence of H3K27ac, H3K4me, Pol II and
other marks indicate that the TFII-I bound region is an en-
hancer element (Supplementary Figure S4). We next cul-
tured K562 cells in the presence of histidinol (HisOH) to
mimic amino acid limitation or with thapsigargin to induce
endoplasmic reticulum stress and then examined several re-
gions across the ATF3 gene locus for RNA production. As
shown in Figure 10B, expression of the ATF3 mRNA, as de-
termined by using primers spanning the junctions of exons
2/3 and exons 3/4, (Junc2 and Junc3), increased by more
than 16-fold in cells treated with 2 mM HisOH for 8 h com-
pared to untreated cells. Importantly, we also detected in-
creased transcription at a non-coding region downstream
of the TFII-I/Pol II binding peak (Tpdn), but upstream of
promoter P2, suggesting release of the paused Pol II. Treat-
ment of K562 cells with 100 nM thapsigargin for 8 h led to
a 5-fold increase of ATF3 transcription (Junc2 and Junc3).
Expression of the EFR3A gene remained unaltered in the
presence or absence of HisOH or thapsigargin demonstrat-
ing that stimulation of elongation of Pol II at this promoter
required different stimuli (Figure 10B). Expression of the
FAM71A gene which is located in close proximity down-
stream of the ATF3 gene was upregulated by almost 60-fold
in response to HisOH treatment. Treatment with thapsigar-
gin did not significantly enhance FAM71A expression over
the Dimethyl Sulfoxide (DMSO) treated control cells.
Next, we examined the binding of TFII-I, Pol II, Topo
II, Elongin A and TAF15, with three specific regions in
the ATF3 gene locus before and after induction of expres-
sion with HisOH (Figure 10C). We restricted the analysis
to HisOH treated cells as we detected more robust induc-
tion of ATF3 under these conditions. At the Pol II peak
upstream of TFII-I binding (Pol II P1b), we detected only
Pol II and low levels of TFII-I. At the TFII-I peak (Tp) we
detected only TFII-I, and HisOH treatment increased the
binding of TFII-I but did not change association of other
proteins in this region. We also examined a region down-
stream of a Pol II peak associated with promoter P2 (Pol II
dn) and found that the association of Pol II increased with
this region after incubating K562 cells with HisOH (Fig-
ure 10C). Importantly, Elongin A was only detectable at the
ATF3 gene locus in HisOH treated cells and the association
of Elongin A was restricted to the promoter P2 controlled
coding region of ATF3. These data suggest that Elongin A
promotes enhanced expression of ATF3 from promoter P2
in the presence of cellular stress, consistent with published
data (41,42). Because we showed that TFII-I interacts with
Elongin A (Figure 7) it is possible that there is an interac-
tion between the TFII-I bound enhancer and promoter P2
that delivers Elongin A to the ATF3 coding region. This hy-
pothesis is supported by ChIA-Pet data, available from the
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Figure 8. Analysis of the occupancy of TFII-I and associated proteins with two expressed and two silent genes in K562 cells. (A, B, C) K562 cells were
subjected to ChIP assays using the antibodies shown at the bottom of the graphs. The precipitated DNA was subjected to qPCR using primers specific
for the expressed GATA1 and DNMT1 (A and B) and the silent OSM and EFR3A (A and C) genes as indicated. The data were normalized to the HS2–3
region and represent the results of two independent experiments with the qPCR performed in triplicate +/− SEM. All data in (B) with respect to binding
of TFs to the GATA1 and DNMT1 genes compared to IgG were statistical significant (P < 0.05) according to student’s t-test. With respect to (C) binding
of all the factors to the OSM gene, except Brg1, compared to IgG revealed statistical significance according to the student’s t-test (P < 0.05). The same is
true for binding to the EFR3A, except for TAF15 and SMARCC1. (D) TFII-I and Pol II occupancy at the EFR3A promoter in K562 cells. The scale refers
to read counts normalized using the peak calling algorithm (MACS). The arrow indicates the direction of transcription.
tions between the TFII-I/Pol II peak upstream of promoter
P1 with the promoter P2 in K562 cells (Supplementary Fig-
ure S5).
Inhibition of TFII-I expression by siRNA did not change
the basal expression levels of the ATF3 gene in K562 cells
(Figure 10D and Supplementary Figure S6). However, the
reduction in TFII-I expression decreased the induction of
ATF3 gene transcription by HisOH. These results show that
TFII-I is required for the stress-induced expression of the
ATF3 gene, which could be mediated by delivery of Elongin
A to the P2 promoter via a looping mechanism.
DISCUSSION
In many ways TFII-I is an unusual TF. It contains multiple
R-repeats that resemble helix-loop-helix proteins, it func-
tions in both cytoplasm and nucleus, and it functions as
an activator and repressor of transcription (1,2). TFII-I ap-
pears to regulate a large number of genes including house-
keeping and tissue-specific genes as well as genes that code
for cell-cycle regulators or proteins involved in response
to cellular stress. In this study, we identified TFII-I inter-
acting proteins and target DNA sequences in human ery-
throleukemia cells. We chose to perform these studies in
K562 cells as these cells have been extensively analyzed in
the context of the human ENCODE project (33,34). The
ENCODE project provides genome wide data of chromatin
associations of a variety of proteins and histone marks in-
volved in the regulation of chromatin structure and tran-
scription.
The genome-wide association analysis revealed that
TFII-I interacted with intragenic as well as intergenic re-
gions. Similar to what was reported by Bayarsaihan et al.
for TFII-I interactions in ES cells and embryonic tissues
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Figure 9. Reduced association of Elongin A at the DNMT1 and EFR3A gene loci in K562 cells expressing TFII-I directed shRNA. (A) K562 cells
expressing TFII-I shRNA (shTFII-I) or SC were subjected to expression analysis using primers specific for the GAPDH, UBB, B2M, PGK1, TFII-I,
DNMT1 and EFR3A genes. Relative expression levels, with levels in SC cells set at 1, are shown. The data represent the results of two independent
experiments with the qPCR performed in triplicate +/− SEM. Reduced expression of TFII-I, DNMT1 and EFR3A was statistically significant (P < 0.05).
(B) Western blot analysis of TFII-I and GAPDH expression in K562 cells expressing TFII-I shRNA (shTFII-I) or SC. (C) TFII-I, Elongin A (TCEB3),
and Pol II occupancy at the DNMT1 and EFR3A gene loci in K562 cells expressing TFII-I shRNA (shTFII-I) or SC. K562 cells were subjected to ChIP
and the purified DNA was analyzed by qPCR using primers specific for the TFII-I binding peak at the DNMT1 and EFR3A gene loci. The data represent
the results of two independent experiments with the qPCR performed in triplicate. Data showing reduced association of TFII-I and Elongin A (TCEB3)
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Figure 10. TFII-I binds immediately downstream of a Pol II peak in the ATF3 gene locus and nutrient stress increased transcription downstream of the
TFII-I/Pol II peak and across the ATF3 gene locus. (A) TFII-I and Pol II occupancy at the ATF3 and FAM71A gene loci in K562 cells. The scale refers
to read counts normalized using the peak calling algorithm (MACS). The arrows indicate the direction of transcription at the two ATF3 promoters (P1
and P2) and the FAM71A promoter. Regions analyzed by RT-PCR to assess RNA abundance are indicated on top of the locus, and regions analyzed
by ChIP are indicated at the bottom. (B) Analysis of ATF3, FAM71A and EFR3A gene expression in K562 cells and in K562 cells treated for 8 h with 2
mM histidinol (HisOH) or 100 nM thapsigargin as indicated. Several regions of the ATF3 gene locus were analyzed including a region downstream of the
TFII-I binding peak (Tpdn), exon/exon junctions 1, 2 and 3 (Junc1, 2 and 3), and a region downstream of promoter P2 (Pol II dn). RNA was extracted
and analyzed as outlined in the legend to Figure 5. The data were from two independent experiments with the qPCR performed in triplicate. Changes in
gene expression across the ATF3 and FAM71A gene locus in response to HiOH treatment revealed statistical significance according to student’s t-test (P
< 0.05). (C) ChIP analysis of TFII-I, TAF15, TCEBP3 (Elongin A), Topo II  and Pol II, at the ATF3 gene locus in K562 cells or K562 cells treated for
8 h with 2 mM HisOH. Cross-linked chromatin was sonicated and precipitated with the respective antibodies, including as a negative control IgG. DNA
was isolated from the precipitate and subjected to qPCR using primers specific for the ATF3 gene locus; Tp, corresponding to the TFII-I peak; Pol II
P1b, a region corresponding to the upstream Pol-II/TFII-I binding peak and Pol II dn, corresponding to a transcribed region of the ATF3 gene. Data
were normalized to a region in the human -globin LCR (HS2/3) and represent the results of two independent experiments with the qPCR performed in
triplicate. Increased binding of Pol II to Pol IIP1b and Pol IIdn, as well as increased binding of TFII-I to Tp, and TCEB3 (Elongin A) to Pol II dn revealed
statistical significance (P < 0.05). (D) ATF3 (Junc 1, 2 and 3, as described in panel B) and control mRNA (TFII-I, PKG1) analysis in K562 cells treated
with 25 nM TFII-I siRNA (siTFII-I) or non-targeting siRNA (nonT) in the presence or absence of histidinol (HisOH, as described in panel B). The data
were from two independent experiments with the qPCR performed in triplicate. Changes in gene expression of ATF3 (Junc2 and Junc3) and TFII-I in
TFII-I siRNA and/or HisOH treated cells, compared to nonT-siRNA treated cells revealed statistical significance according to student’s t-test (P < 0.05).
Data with error bars for (C) and (D) are presented in Supplementary Figure S5.
I binding and the expression levels of genes located close
to TFII-I binding sites in K562 cells. Comparison with
the ENCODE data revealed that TFII-I binding peaks at
silent genes was associated with repressed histone marks
like H3K27me3, whereas peaks close to expressed genes
were associated with histone marks typically found in active
chromatin like H3K4me3 at proximal sites or H3K4me1 at
distal sites. We identified three components of SWI/SNF
chromatin remodeling complexes as TFII-I interacting pro-
teins, including the ATPase Brg1 and associated proteins
SMARCC1 and SMARCC2. Brg1 containing chromatin re-
modeling complexes have been associated with both activa-
tion and repression of transcription (45), similar to what
has been reported for TFII-I. However, in this study we
only found Brg1 associations with TFII-I bound to active
genes. Previous studies found that Topo II  and  inter-
act with Brg1 containing SWI/SNF chromatin remodeling
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chromatin remodeling complexes including Topo II activity
to promoters and other DNA regulatory elements.
One interesting aspect of the current study is the observa-
tion that TFII-I preferentially binds upstream of the TSS in
expressed genes, and downstream, or upstream and down-
stream, of the TSS in repressed genes. A previous study by
the Roeder laboratory found that TFII-I interacts with a
downstream element in the IgH gene and that it functions
as both repressor and activator at this site (23). Activation is
mediated by the replacement of HDAC with Oca-B, which
then mediates the interaction between the promoter and an
enhancer. This or similar scenarios could also be envisioned
for other repressed genes that have TFII-I bound down-
stream of the TSS (i.e. OSM, EFR3A, ZAP 70 and NCF1,
Figure 3).
The analysis of DNA sequences common to the TFII-
I peaks revealed some known and novel binding sites. For
example, binding of TFII-I to E-box sequences has been
shown before (16). It may be important that the current
analysis identified E-box variants predicted to interact with
the snail repressor proteins (46). Previous studies identi-
fied initiator (INR) and the downstream promoter element
(DPE) as sites of TFII-I recruitment (1,2). We observed an
enrichment for HMG-box protein (Hbp1) binding sites as
well as binding sites for the TFs NFATC and GATA at
TFII-I peaks. NFATC activity is regulated by calcium and
cytoplasmic TFII-I inhibits the influx of calcium through
interaction with PLC- (13,47). Thus, nuclear transloca-
tion of TFII-I may increase calcium influx and activation
of NFAT TFs.
Bayarsaihan et al. identified additional TF sites associ-
ated with TFII-I binding events in ChIP/chip experiments
in ES cells and embryonic tissues (5,22). It is possible that
the focus on the TFII-I delta isoform in this study led to a
more restricted number of binding sites (5,22). Analysis of
TFII-I peaks with other DNA binding events in K562 cells
revealed frequent association with the binding of E2F6 and
E2F4.
Interestingly, while overall the GO analysis did not reveal
specific clusters of genes regulated by TFII-I in K562 cells,
we found that TFII-I peaks associated with stress respon-
sive genes that correlated with increased presence of the
BRE element (Table 1). Many stress responsive genes har-
bor paused RNA polymerase II at the promoter (48), and
previous data have shown that TFII-I regulates stress re-
sponsive genes (1,2). It is thus possible that TFII-I regulates
Pol II pausing and/or release from pausing at these genes.
Indeed, we identified several genes, including the ATF3, CS-
B, CBX1 (Hp1 beta) and EIF2AK1 genes, at which TFII-I
binds immediately downstream of a Pol II peak (Supple-
mentary Figure S3). Moreover, two components implicated
in the response to cellular stress, Elongin A and TAF15
(40,41), were found to associate with TFII-I in this study.
TAF15, formerly known as TAF68, is, as the name im-
plies, a TAF involved in basal Pol II transcription (49).
TAF15 contains RNA binding domains and has been
shown to interact with components of the spliceosome in-
cluding the U1snRNP (50). Like Elongin A, TAF15 has
been implicated in the cellular response to stress (40). In Co-
IP experiments the interaction between TFII-I and TAF15
was found to be very strong. The interaction with TAF15
and the unusual binding patterns of TFII-I in expressed, re-
pressed and inducible genes could hint to a new activity of
TFII-I. Recently, the Sharp laboratory presented evidence
that the directionality of transcription at many promoters
is regulated by U1snRNP, which appears to protect sense
transcripts from being cleaved by the polyadenylation and
cleavage complex (51). Perhaps TFII-I and TAF 15 together
recruit U1snRNP to the 5′ end of genes or to Pol II bound
enhancer elements.
Elongin A is an activator of transcription elongation and
has been shown to help Pol II overcome the paused state
(52). In this respect, it is interesting to note that we found
both TFII-I and Elongin A together with paused Pol II at
the promoter of the repressed EFR3A gene. Elongin A in-
teracts with two other components, Elongin B and C and,
in addition to stimulating transcription elongation, Elon-
gin A has been shown to recruit Elongin B/C and ubiq-
uitinylating activities that lead to the degradation and re-
moval of paused Pol II (53). Therefore, TFII-I and Elon-
gin A could exert negative effects on transcription but could
also be involved in activating transcription upon receiving
specific stress signals. Interestingly, the association of Elon-
gin A but not Pol II with the EFR3A gene requires TFII-I
(Figure 9). Expression of the EFR3A gene is very low in
K562 cells (33,34) and is further reduced upon reduction of
TFII-I expression. Our data show that TFII-I is required
for the recruitment of Elongin A to the EFR3A promoter
and suggest that it does so by directly interacting with this
elongation factor (Figure 7).
The bzip TF ATF3 has been implicated as a key regula-
tory molecule in pathological states as cancer (54) and the
inflammatory response (55). ATF3 often serves as a tran-
scriptional repressor, and has been shown to recruit multi-
ple HDAC activities during autorepression of its own gene
(56). The ATF3 gene has been reported to have two pro-
moters (P1 and P2, Figure 10A) separated by about 40
kb, which are regulated in a cell-type specific manner (44).
The downstream promoter P2 has been more extensively
studied and contains proximal regulatory elements that re-
spond to a wide variety of extracellular stimuli, including
hormones (57), non-steroidal anti-inflammatory drugs (58),
amino acid limitation (59) and ER stress (43). TFII-I in-
teracts with an element located 5 kb upstream of promoter
P1 in the ATF3 gene locus and there is a binding peak for
Pol II immediately upstream of the TFII-I site. This ele-
ment exhibits characteristics of an enhancer including in-
creased levels of H3K4me, H3K27ac and p300 (Supplemen-
tary Figure S4). Transcripts are detectable only upstream
of the TFII-I binding peak suggesting that TFII-I prevents
transcription elongation at this site (Figure 10A). Indeed,
induction of transcription by HisOH increased transcrip-
tion downstream of the TFII-I/Pol II peak and through-
out the ATF3 gene locus. Induction of transcription did
not cause the dissociation of TFII-I from the ATF3 gene
locus, but rather increased its association suggesting that it
is involved in both negative and positive aspects of ATF3
gene transcription. This function would be similar to what
has been described for TFII-I’s role at an immunoglobulin
gene locus (23). Importantly, HisOH induced higher levels
of promoter P2-mediated transcription of the ATF3 cod-
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required TFII-I and correlated with enhanced association
of Elongin A (TCEB3) with the ATF3 coding region. The
Pol II ChIA-Pet data from The ENCODE Project Consor-
tium (33,34) show that the TFII-I/Pol II bound region in-
teracts with promoter P2 in K562 cells and, moreover, that it
does not reveal any other interactions (Supplementary Fig-
ure S5). This strongly suggests that this element functions as
an enhancer for promoter P2 in the ATF3 gene locus. Fu-
ture studies will be directed toward testing the hypothesis
that the upstream TFII-I bound enhancer associates with
P2 and that Elongin A is recruited to this locus in a TFII-I
dependent manner.
Taken together, our data reveal novel aspects of TFII-
I protein–protein interactions and function that will guide
our future studies on the association with other transcrip-
tion regulators and the physiological consequences of their
actions on specific genes. One focus will be to examine
the functional relationship among TFII-I, Elongin A and
TAF15 in controlling gene expression in response to cellu-
lar stress.
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